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Endothelial cells line the inside of blood vessels and are activated by angiogenic cues to 
promote the formation of new blood vessel sprouts, a process called sprouting 
angiogenesis. For sprouting to be initiated, endothelial cells first modulate their 
adherens junctions to allow for cell rearrangements. The Bone Morphogenetic Protein 
(BMP) pathway is a potent regulator of angiogenesis. SMAD6, a major intracellular 
inhibitor of BMP signaling, is required for homeostasis of the cardiovascular system in 
the adult. Here, we examine the function of SMAD6 during mouse embryonic 
development, and find that global loss of Smad6 results in embryonic vessel 
hemorrhage and is lethal by postnatal day (P)0 with moderate penetrance. SMAD6 is 
expressed developmentally in the heart and in a subset of arteries. We show that loss of 
Smad6 also leads to angiogenic defects in the postnatal retina, as Smad6-/- retinas 
show increased sprouting at the vascular front and in the retina plexus. Closer 
examination revealed disorganized localization of the major adherens junction protein in 
endothelial cells, VE-cadherin, in Smad6-/- retinas. In vitro, knockdown of SMAD6 
results in increased VE-cadherin area and increased VE-cadherin internalization, 
suggesting activated endothelial cells with decreased barrier function. Thus, we 
highlight novel roles for SMAD6 in the stabilization of endothelial cell junctions and 
angiogenesis that can be used to advise blood vessel therapies.   
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CHAPTER 1: General Introduction 
 
1.1 Sprouting angiogenesis 
 
My research project is focused on the regulation of sprouting angiogenesis and 
endothelial cell quiescence vs. activation. This section describes different processes by 
which blood vessels form, and the signaling pathways that regulate these processes. 
 
Blood vessel formation 
 Blood vessels form through vasculogenesis, the de novo formation of blood 
vessels, and subsequent angiogenesis, the growth of new vessels from pre-existing 
vessels. In vasculogenesis, endothelial cell progenitors, termed angioblasts, arise from 
the mesoderm and coalesce to form cords at precise locations in the embryo [1]. These 
linear aggregates of cells must then open to form tubes that carry blood. To do this, 
angioblasts mature into endothelial cells, changing their cell shape from cuboidal to 
flattened and their junctional contacts with neighboring cells to open a lumen in a 
process called tubulogenesis [2]. Thus, the primitive vascular network is formed and is 
then expanded upon by angiogenesis and remodeled to form a functional circulatory 
system consisting of arteries, veins, and capillaries. A mature blood vessel system of 
smaller and larger vessels is formed by sprouting, remodeling, pruning and 
intussusception [3]. This chapter focuses on sprouting angiogenesis, which is examined 
in detail in the following section.  
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Blood vessel sprout initiation 
Sprouting angiogenesis occurs when endothelial cells are activated by an 
angiogenic cue and sprout from a parent vessel to form a new, functional blood vessel 
[3]. Once activated, endothelial cells reorganize their junctional contacts, degrade the 
basement membrane and the extracellular matrix, proliferate, migrate, open a lumen, 
and stabilize their junctions to form mature endothelium [4-6]. Tip cells, endothelial cells 
that are selected for sprouting, are activated by extracellular stimuli and guidance cues 
and lead the new sprout, followed by stalk cells, which are important for sprout 
elongation and lumen formation [7-10]. The tip cell initiates signaling that inhibits 
sprouting in neighboring endothelial cells, and maintaining this molecular heterogeneity 
is essential for proper vessel network formation [4, 8, 10].  
 
Regulation of sprouting angiogenesis 
Sprouting angiogenesis involves many levels of regulation that control 
endothelial cell responsiveness and manage network expansion [8]. One of the main 
signaling pathways regulating angiogenesis is vascular endothelial growth factor-A 
(VEGF-A) pathway [11, 12]. VEGF-A ligand binding to VEGF receptor 2 (VEGFR2) on 
endothelial cells promotes endothelial cell proliferation, differentiation, and sprouting [4]. 
Deletion of Vegfa leads to embryonic lethality with vascular defects, revealing its 
importance during development [13, 14]. Notch signaling, which requires cell-cell 
contact, promotes coordinated angiogenesis via lateral inhibition. Tip cells express the 
Notch ligand delta-like protein 4 (Dll4) in response to VEGF-A, activating Notch 
signaling in neighboring endothelial cells to suppress sprouting of these cells [4, 6, 8]. 
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Disruption of Dll4-Notch relations have been shown to influence angiogenic sprouting 
and branching in many models [15-18]. Many other pathways regulate angiogenesis, 
such as Wnt, fibroblast growth factor (FGF), and bone morphogenetic protein (BMP), 
and crosstalk between these pathways contributes to the complex heterogeneity of 
endothelial cells that is required for formation of a proper circulatory system [5, 8, 19-
23]. BMP signaling regulation of angiogenesis is discussed in greater detail in a later 
section.  
 
1.1 Angiogenesis in development, the adult, and disease  
 
I examined angiogenesis during development of the postnatal mouse retina. Here, I 
focus on angiogenesis in distinct contexts, specifically developmental, physiological, 
and pathological angiogenesis.    
 
Developmental angiogenesis  
 Blood vessels are required for proper development across all vertebrates. 
Angiogenesis is essential during development, as the cardiovascular system is the first 
organ to form and the embryo relies on the vessel network for its growth. Sprouting 
angiogenesis occurs both in the embryonic yolk sac and in the embryo, especially 
during organogenesis, and is driven by hypoxia [3, 24]. Perturbations in angiogenesis 
often leads to early embryonic lethality. For example, loss of a single allele of Vegfa 
leads to embryonic vascular defects [14, 25]. Deletion of the endothelial receptor 
tyrosine kinase (TIE2) inhibits sprouting of capillaries into the brain, resulting in lethality 
around embryonic day (E)10 [26]. Endothelial-specific knockout of Notch1 reveals intact 
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vasculogenesis but defective angiogenesis, such as impaired remodeling of the 
primitive network and defective blood vessel maturation [27]. These examples highlight 
the requirement for normal angiogenesis in the embryo. Many more signaling pathways 
contribute to developmental angiogenesis to build the complex network of vessels 
required for life.   
 
Physiological angiogenesis 
 Most endothelial cells in adult vessels are in a quiescent, resting state and are 
non-mitogenic [3]. Angiogenesis in the adult requires an inflammatory response, 
whereby inflammatory cells are recruited to secrete growth factors to produce new 
vessels [28]. Growth of new vessels is limited in the adult but occurs during pregnancy, 
the menstrual cycle, skeletal growth, and wound healing.  
Angiogenesis is a fundamental process for growth of a fetus, as the fetus needs 
adequate nutrient supply from the mother for its growth. Angiogenesis is also important 
during implantation to establish pregnancy [28]. Pro-angiogenic molecules such as 
VEGF-A, placental growth factor (PlGF), and basic FGF (bFGF) are induced by 
hormones and increase maternal vessel permeability to allow endothelial cells to 
proliferate and migrate [29]. There are permanent angiogenic changes to the uterine 
vasculature is response to pregnancy, but when pregnancy is complete, some 
endothelial cells apoptose to reduce the vascular network and growth factors are no 
longer secreted to prevent continued sprouting [29]. Disturbances in uterine blood 
supply can lead to pre-eclampsia, which is discussed in the following section.  
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Pathological angiogenesis 
Pathological angiogenesis is similar to physiological angiogenesis in terms of the 
coordinated responses that drive the formation of new vessels, however, pathological 
angiogenesis is not resolved and does not shut off when vascular perfusion is achieved 
[28]. Pathological angiogenesis is therefore associated with disease and can assist 
disease in multiple ways. For example, tumor cells secrete pro-angiogenic factors to aid 
the tumors rapid growth, and new blood vessels give tumor cells more opportunities to 
intravasate and metastasize to new locations [30, 31]. 
 Another example of pathological angiogenesis is pre-eclampsia, which is a 
leading cause of perinatal morbidity and mortality. In pre-eclampsia, regulation of 
vascular growth between the mother and the fetus is disturbed leading to faulty 
formation of the placenta [29]. Recent studies suggest that abnormal growth factor 
expression, such as lower VEGF-A and higher levels of the anti-angiogenic factors Flt1 
and Endoglin, in the placenta of women with pre-eclampsia leads to widespread 
maternal endothelial dysfunction [32, 33]. It is critical to understand how these 
pathogenic factors are dysregulated to detect and treat pre-eclampsia.  
 
 
1.2 BMP signaling in development and disease 
 
My thesis project examines the role of a BMP signaling pathway protein during 
development. In this section, I provide background on BMP signaling and examine what 
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BMP signaling overview 
 BMPs are members of the transforming growth factor-b (TGF-b) superfamily of 
proteins. BMP ligands signal through a heterotetrameric protein complex at the cell 
surface consisting of serine-threonine kinase Type II and Type I receptors. Ligand 
binding promotes the phosphorylation of the Type I receptors by the Type II receptors, 
which in turn transduce signaling through SMAD and non-SMAD signaling pathways 
[34, 35]. SMAD signaling is initiated by phosphorylation of the receptor-associated (R)-
SMADs (SMADs 1, 5, and 8), which then bind to SMAD4 and translocate to the nucleus 
where they bind DNA to facilitate downstream gene transcription (Figure 1.1). Non-
canonical signaling through BMPs has also been identified. ERK/MAPK and p38 
pathways are activated by BMPs to induce cell differentiation and proliferation [34, 35]. 
About 20 BMP ligands have been identified with different affinities for different receptor 
groupings. There are three Type I receptors that bind BMPs, ALKs 2, 3, and 6, and one 
Type II receptor, BMPRII [24]. Thus, the BMP pathway and its regulation is complex due 
to a large number of combinations of ligand and receptors. There are multiple intra- and 
extracellular inhibitors of BMP signaling, which will be discussed in greater detail in a 
later section.  
 
BMP signaling in development 
 When discovered, BMPs were named for their ability to induce bone formation, 
but now are known to play critical roles in the development of many organ systems [35]. 
BMP ligands, receptors, and extracellular antagonists have unique expression patterns 
during embryogenesis with some overlap, suggesting that different combinations are 
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essential for the development of various organs. During early embryogenesis, BMPs are 
expressed in the dorsal-most cells of the neural tube and evidence shows that they are 
key regulators of dorsal cell identity in the spinal neural tube [36]. BMP2 and BMP4 
knockout mice are embryonic lethal, and BMP1, BMP7, and BMP11 knockouts die 
shortly after birth [24]. Global loss of most BMP receptors and SMAD proteins results in 
embryonic lethality and an array of abnormalities, most notably cardiac and mesoderm 
formation defects. For example, BMPRII is required for mesoderm formation and 
gastrulation and BMPRII mutant mice die around E9.5 [37]. SMAD1 knockouts also die 
around E9.5 with defects in allantois formation and SMAD4 knockouts die at about E7.5 
from gastrulation defects [38, 39]. Conditional deletion of BMP pathway proteins in 
specific organ systems has elucidated many other roles for BMP members.  
 
BMP signaling in angiogenesis 
 BMP signaling is a potent regulator of angiogenesis, and angiogenesis is 
promoted or inhibited by different BMP pathway members. In zebrafish, BMP signaling 
is restricted to the venous endothelial cells, whereas VEGF-A signaling promotes 
sprouting from arterial endothelial cells [23]. Overexpression of Bmp2b resulted in 
aberrant sprouting from the caudal vein plexus of zebrafish, but not from the dorsal 
aorta, suggesting differential responsiveness to angiogenic cues in different vascular 
beds [23, 40]. BMP2 and BMP6 ligands were recently shown to promote angiogenesis 
in a 3D angiogenesis model using human umbilical vein endothelial cells (HUVEC) [15]. 
Conversely, endothelial-specific knockout of both SMAD1 and SMAD5 leads to 
increased formation of tip cells in the hindbrain of E9.5 embryos [22]. These double 
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knockout mice die early during embryogenesis, and while vasculogenesis occurs 
normally, remodeling of the primitive vascular plexi is disturbed, suggesting that 
angiogenic defects contribute to lethality [22]. Recently, it was shown that vascular 
deletion of ALK2, ALK3, or BMPRII leads to increased sprouting and/or branching in the 
postnatal mouse retinal vasculature. However, vascular deletion of ALK1 increased 
sprouting at the retinal vascular front [41]. Similarly, BMP9, which has high affinity for 
ALK1, functions as an anti-angiogenic signal [42-44]. These examples emphasize the 
complexity of the BMP pathway, and a full understanding of how BMP pathway 
members regulate angiogenesis in different vascular beds should facilitate innovative 
and efficacious blood vessel therapies. 
  
BMP signaling in disease 
 Regulation of BMP signaling is required for homeostasis in many adult tissues. 
BMP signaling is upregulated in many types of cancer and is linked to a number of 
human vascular diseases. For example, hereditary hemorrhagic telangiectasia (HHT) is 
a rare genetic disorder that leads to abnormal blood vessel formation in the skin, lungs, 
and brain. Mutations in the endoglin and BMP Type I receptor, ALK1, are associated 
with HHT. [45] [46]. ALK1/BMP9 signaling is anti-angiogenic, keeping endothelial cells 
in a stable state, and thus ALK1 and BMP9 are ideal therapeutic targets in diseases 
related to angiogenesis, such as cancer and HHT [47]. Pulmonary arterial hypertension 
(PAH) results from haploinsufficiency of BMPR2 in mice [48]. Patients with PAH have 
high pulmonary artery pressure leading to heart failure because the heart pumps harder 
to compensate for the narrowing or blockage of the lung [45, 46]. Deregulation of BMP 
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signaling via increased levels of BMP6 ligand can lead to cerebral cavernous 
malformation (CCM), severe hemorrhaging of cranial vessels [49]. Overall, these 
studies reveal the significance of the BMP pathway in maintaining a balanced, stable 
vasculature in the adult to prevent disease.  
 
1.3 SMAD6: a major intracellular BMP inhibitor  
 
I found that deletion of SMAD6 in mice leads to embryonic hemorrhage and increased 
sprouting angiogenesis in the postnatal retina. This section overviews SMAD6 structure 
and function in BMP signaling as well as what is known about SMAD6 in angiogenesis 
and disease.    
 
BMP signaling inhibitors  
 BMP signaling is regulated extracellularly and intracellularly. BMP antagonists 
regulate the activity of BMPs through direct association with the ligands, thus preventing 
binding to their cognate receptors [50, 51]. There are many BMP antagonists, and they 
are regulated spatiotemporally during embryogenesis and postnatal development to 
precisely limit BMP in specific areas. BMP ligands are also spatiotemporally regulated, 
suggesting that a combination of antagonists and ligands is critical for development of 
certain organs [23]. For example, BMP ligand expression does not overlap with the 
extracellular inhibitor noggin, proposing that the regions where noggin is present require 
active extracellular regulation of BMP signaling [52]. The BMP antagonists, chordin and 
noggin, bind BMP2 and BMP4 to prevent their binding to receptors. Double knockout 
mice for chordin and noggin have abnormal left to right patterning, mesoderm formation 
defects, and defects in development of head and facial structures [50]. Gremlin, another 
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extracellular inhibitor, also binds BMP2 and BMP4 and loss of gremlin leads to early 
postnatal lethality by causing defects in lung septation and complete absence of kidney 
development [50].  
 SMAD6 and SMAD7 are intracellular inhibitory SMADs (I-SMADs). SMAD7 can 
block BMP and TGF-b signaling, whereas SMAD6 preferentially blocks BMP signaling 
[53, 54]. I-SMADs inhibit signaling in a number of different manners: 1) blockade of R-
SMAD activation by competing for binding sites on Type 1 receptors; 2) competition with 
R-SMADs in binding with SMAD4; 3) recruitment of Smurf family members, targeting 
the R-SMADs for degradation; and 4) suppressing BMP downstream target inhibitor of 
DNA binding 1 (Id1) transcription in the nucleus (Figure 1.1) [35, 54-56]. Recently, a 
new mechanism was proposed for SMAD6 whereby SMAD6 associates with BMP Type 
I receptors in the absence of ligand and subsequent ligand engagement induces its 
dissociation and binding to BMPRII, enabling SMAD activation in response to ligand 
stimulation (Figure 1.2) [57]. This model proposes post-translational modifications on 
SMAD6 as a mechanism to regulate BMP signaling and enable individual cells to adjust 
their threshold to BMP responsiveness. My studies focus on the function of the I-SMAD, 
SMAD6, in endothelial cells during development. 
 
SMAD6 structure and function 
 The SMAD6 protein consists of a highly conserved carboxyl-terminal MH2 
domain which binds receptors and other SMADs [56]. The N-terminal region of SMAD6 
is highly divergent compared to other SMADs and not conserved across species. 
Therefore, the MH2 domain is thought to be the functional domain of the protein [35, 
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53]. Although the N-terminal region is thought to be unstructured and is highly variable 
among species, several studies suggest it is important for SMAD6 function. For 
example, methylation of SMAD6, which removes it from BMP Type 1 receptors and 
allows for BMP activation, occurs in the N-terminal region [57]. This suggests this region 
is functionally important, via post-translational modifications and/or its binding to cell 
type specific proteins. 
 Gavin et al. generated a Smad6 knockout mouse by inserting a LacZ-neomycin 
resistance cassette into the MH2 domain of SMAD6. The mutant mice exhibit abnormal 
Mendelian ratios at birth and a low chance of survival to adulthood. Adult knockout mice 
have cardiovascular defects, such as hyperplastic thickening of cardiac valves, dilated 
blood vessels, and increased blood pressure [58]. This study also examined SMAD6 
expression using X-gal staining and found expression in the outflow tract of the heart 
during development and in heart valves, lungs, and larger arteries in the adult. Another 
study concluded that loss of Smad6 causes craniofacial, axial, and appendicular 
skeletal defects due to increased BMP signaling [59]. Both studies saw a loss of mutant 
mice before or right after birth, however, no studies have addressed the developmental 
role of SMAD6 that account for the death of these mutant mice. 
 SMAD6 regulates angiogenesis in vitro and in zebrafish [15]. Knockdown of 
SMAD6 in HUVEC using siRNA leads to increased branching of sprouts in a 3D 
angiogenesis assay. Use of a CRISPRi strategy to reduce smad6b in the vasculature in 
zebrafish revealed ectopic intersegmental vessels from the dorsal aorta with Bmp2b 
overexpression [15]. It was also discovered that Notch signaling regulates SMAD6 
levels to regulate endothelial cell responsiveness to BMP signaling. Notch regulates the 
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tip cell vs. stalk cell phenotype in endothelial cells within a sprout, and this model 
proposes that interplay between Notch and BMP through SMAD6 levels results in 
heterogeneity in endothelial cells that determines their position within the sprout [15].  
 
SMAD6 in disease  
 Changes or mutations in SMAD6 are linked to disease. As mentioned in the 
previous section, Smad6 knockout mice have increased blood pressure compared to 
wildtype littermates [58]. More recently, SMAD6 was shown to contribute to a number of 
human diseases. SMAD6 expression is correlated with reduced survival in lung cancer 
patients and knockdown of SMAD6 resulted in cell cycle arrest and apoptosis in a lung 
cancer cell line, suggesting that SMAD6 supports lung cancer cell growth and survival 
[60]. Similarly, overexpression of Smad6 in a zebrafish xenograft model enhanced 
aggressiveness of breast cancer cells and increased invasion [61]. Because SMAD6 
expression is linked to lung cancer cell growth, targeted inactivation of SMAD6 may aid 
lung cancer treatments.   
Tan et al. provided the first report of a human disease phenotype related to 
genetic variation in SMAD6. Deleterious variants in the SMAD6 gene predispose 
patients to congenital cardiovascular malformations [62]. A recent study determined that 
SMAD6 is an important contributor to the etiology of bicuspid aortic valve (BAV) 
associated thoracic aortic aneurysm (TAA). In the past, it was thought that BAV-related 
TAA arose as a hemodynamic consequence of the valve defect. However, Gillis et al. 
linked mutations in SMAD6 to BAV associated TAA, revealing a new function for 
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SMAD6 in prevention of aortic aneurysm in the adult [63]. It is therefore critical to 
understand the function of SMAD6 during development to inform these phenotypes.  
 
1.4 Adherens junction regulation and vessel stability 
 
My thesis project uncovered a novel role for SMAD6 in organization of endothelial cell 
adherens junctions. Here, I describe the adherens junction complex, focusing on VE-
cadherin cellular localization and function in maintaining a stable vessel barrier.   
 
Endothelial cell adherens junctions  
Endothelial cell-cell junctions need to be maintained after lumen formation to 
prevent excessive vessel leakage [4]. Tight junctions consist of transmembrane 
proteins, such as occludin, and cytoplasmic scaffolding proteins, such as ZO-1, and 
regulate the movement of ions and solutes in-between cells [64]. Adherens junctions 
are primarily made up of members of the cadherin and catenin families. Cadherins 
assemble multimeric complexes at the cell borders, while catenins link cadherins to the 
actin cytoskeleton and microtubules [2]. Cadherins, such as E-cadherin and N-cadherin, 
interact homophilically in trans and form lateral interactions in cis to form a zipper-like 
structure [65-68]. Catenin family members include p120-catenin, b-catenin, and a-
catenin. Other adhesion molecules, such as platelet endothelial cell adhesion molecule 
(PECAM), are located at the junction between two cells but are also found in the 
membrane away from endothelial junctions [66, 69, 70]. Endothelial junctions have the 
critical task of maintaining vascular integrity. Cells and solutes cross the endothelial 
barrier through gap formations at intercellular contacts when cells are exposed to 
permeability increasing agents, and these gaps promptly close to restore the endothelial 
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barrier [66, 68, 71]. Vascular permeability also increases due to phosphorylation and 
partial internalization of adhesive proteins. In this instance, much of the adherens 
junction architecture is preserved even though permeability is increased [72-74]. 
Permeability and adherens junction strength differs depending on the vessel’s 
surrounding tissue. For example, in the brain, exceptionally limited permeability is 
needed to maintain the blood brain barrier and thus the brain requires a well-developed 
network of tight and adherens junctions [68]. Because adherens junctions control vessel 
permeability, dismantling of adherens junctions can lead to pathologies, such as 
inflammation. 
 
VE-cadherin function in vascular integrity 
Adherens junctions in endothelial cells are largely composed of vascular 
endothelial cadherin (VE-cadherin), a transmembrane protein that can be internalized 
into the cell to control vascular integrity [75]. During mouse embryo development, VE-
cadherin mutations lead to disrupted vascular development and early lethality, revealing 
a critical role for VE-cadherin in maintaining vessel stability [76, 77]. VE-cadherin is also 
important for angiogenesis as it contributes to processes such as establishment of cell 
polarity, tubulogenesis, and rearrangement of the cytoskeleton [70, 78, 79]. 
Phosphorylation of VE-cadherin promotes its internalization in to the cell and is 
associated with disrupted adherens junctions and increased permeability. Thus, VE-
cadherin localization can be used as a readout or quiescent vs. activated endothelial 
cells. Straight and linear VE-cadherin localization indicates a stable junction and 
quiescent cells, whereas serrated and punctate localization indicates VE-cadherin 
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internalization and motile cells [80, 81]. Blood vessel networks do not form correctly if 
VE-cadherin is continuously phosphorylated and thus, it is critical to regulate 
phosphorylation of VE-cadherin to maintain a strong endothelial barrier [82].  
VEGF-A can promote tyrosine and serine phosphorylation of VE-cadherin and its 
binding partners [83, 84]. In one mechanism, VEGF-A activates SRC kinase, which 
phosphorylates VAV2, leading to Rac, a small GTPase, activation. Activation of Rac 
results in serine 665 phosphorylation on VE-cadherin, resulting in its internalization and 
increased permeability [84]. Interestingly, BMP signaling has recently been shown to 
promote VE-cadherin endocytosis upon BMP6 ligand binding (Figure 1.2) [85]. Initiation 
of BMP signaling causes a series of phosphorylation events that start with SRC and 
result with the phosphorylation of VE-cadherin. SRC remains in an inactive state 
through intramolecular association of its domains and is activated in response to cellular 
signals that disrupt these interactions to produce an active kinase [86]. SRC has also 
been shown to physically associate with BMPRII (Figure 1.2) [87, 88]. Phosphorylation 
of VE-cadherin causes its endocytosis and thus, BMP signaling regulates endothelial 
cell permeability and barrier function [85]. 
 
VE-cadherin and blood vessel hemorrhage 
 The prospect of controlling vascular permeability has many therapeutic 
implications. For example, edema can result from lasting changes in permeability, 
leading to an increase in ischemic tissue injury in conditions such as stroke [89]. 
Additionally, tumor cells are able to penetrate vessels with decreased barrier function to 
metastasize to other organs and tissues. Hemorrhage, the escape of blood through a 
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ruptured blood vessel, can also be a consequence of vascular fragility. Embryonic 
hemorrhage due to gene mutations can cause lethality in mice and zebrafish. When VE-
cadherin expression is partially reduced in zebrafish, hemorrhage in the head and near 
the aortic arches occurs due to fragile vessels. This suggests the partial internalization 
or change in function in VE-cadherin leads to vessel instability [90]. Furthermore, in 
adult mice, injection of anti-VE-cadherin antibodies leads to profound increases in 
permeability, vascular fragility, and hemorrhage [91]. Intriguingly, a newfound Rho-
associated protein kinase (ROCK) inhibitor prevents cerebral hemorrhage in zebrafish 
by increasing VE-cadherin at the cell membrane [92]. This suggests that VE-cadherin 
localization is important in maintaining endothelial barrier function and preventing vessel 





Many signaling pathways regulate sprouting angiogenesis, and endothelial cell 
heterogeneity is required to set up and maintain a complex vessel network. 
Dysregulation of endothelial cell signaling can have severe consequences on embryonic 
development and lead to numerous pathologies in adults. Here, I show that loss of 
SMAD6 leads to embryonic hemorrhage and excess retinal vessel sprouting. These 
studies suggest that SMAD6 contributes to vessel stability in the embryo and regulates 
vascular patterning and sprouting in the postnatal mouse retina.  
Endothelial cell-cell junctions are critical for maintaining permeability and stability 
of blood vessels. They are also important in sprouting angiogenesis, as endothelial cells 
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must change their junctional contacts before proliferation and migration into the matrix. 
VE-cadherin is a vascular specific cadherin that forms a zipper like structure between 
cells to create a firm boundary. It can be endocytosed into the cell upon activation by 
growth factors, such as VEGF or BMP, or in the presence of a permeability increasing 
agent. Here, I demonstrate that SMAD6 is an important regulator of VE-cadherin cellular 
localization and appears to control vessel sprouting by stabilizing endothelial adherens 
junctions.   
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1.6 Figures 
 
Figure 1.1 Mechanisms of BMP signaling inhibition by SMAD6. 
 
SMAD6 blocks BMP signaling in these ways: 1) SMAD6 binds to Type 1 receptors to 
block phosphorylation SMADs 1, 5, and 8; 2) SMAD6 competes with SMADs 1, 5, and 8 
by binding to SMAD4; 3) SMAD6 recruits SMURF family members to target SMADs 1, 
5, and 8 for degradation; 4) SMAD6 suppresses BMP target gene, Id1, transcription in 
the nucleus.   
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Figure 1.2 BMP signaling pathway and VE-cadherin internalization. 
 
In absence of BMP ligand, SMAD6 is bound to Type I receptors to block downstream 
SMAD signaling. A stable junction is formed between endothelial cells through VE-
cadherin contacts at the cell surface. Upon BMP ligand binding, SMAD6 is methylated 
by PRMT1 and binds to the Type II receptor. This allows for SMADs 1, 5, and 8 to be 
phosphorylated, form a complex with SMAD4, and translocate in to the nucleus to 
induce transcription of downstream target genes. BMP ligand promotes SRC activation 
and SRC then phosphorylates VE-cadherin, resulting in internalization of VE-cadherin 
and an activated endothelial cell. Our data demonstrates SMAD6 regulates VE-cadherin 
localization through an unknown mechanism. Red arrows represent unknown 
relationships. 
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Figure 1.3 The structure of SMAD6.  
 
Structure of the SMAD6 protein. SMAD6 consists of a poorly conserved N-terminal 
region (orange) and a highly conserved MH2 domain (blue). SMAD6 is methylated in 
the N-terminal region (green) upon BMP ligand binding to the BMP receptor complex.  
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CHAPTER II: Developmental SMAD6 Loss Leads to Blood Vessel Hemorrhage and 





The BMP pathway regulates developmental processes including angiogenesis, yet its 
signaling outputs are complex and context-dependent. Recently, we showed that SMAD6, an 
intracellular BMP inhibitor expressed in endothelial cells, decreases vessel sprouting and 
branching both in vitro and in zebrafish. Genetic deletion of SMAD6 in mice results in poorly 
characterized cardiovascular defects and lethality. Here, we analyzed the effects of SMAD6 
loss on vascular function during murine development. SMAD6 was expressed in a subset of 
blood vessels throughout development, primarily in arteries, while expression outside of the 
vasculature was largely confined to developing cardiac valves with no obvious phenotype. 
Mice deficient in SMAD6 died during late gestation and early stages of postnatal development, 
and this lethality was associated with vessel hemorrhage. Mice that survived past birth had 
increased branching and sprouting of developing postnatal retinal vessels and disorganized 
adherens junctions. In vitro, knockdown of SMAD6 led to abnormal endothelial cell adherens 
junctions and increased VE-cadherin endocytosis, indicative of activated endothelium. Thus, 
                                            
1 This chapter is adapted from a paper submitted to Developmental Biology in 2018. I performed all of the 
experiments and wrote the first draft of the manuscript. Dr. Victoria Bautch edited and added to my 
original draft. Dr. Kevin Mouillesseaux quantified VE-cadherin area in Figure 2.4 and Dr. Diana Chong 
assisted with retina dissections.  
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SMAD6 is essential for proper blood vessel function during murine development, where it 
appears to stabilize endothelial junctions to prevent hemorrhage and aberrant angiogenesis.  
 
2.2 Introduction  
Angiogenesis, the growth of new blood vessels from pre-existing vessels, is 
essential for proper development, as the cardiovascular system is the first to form and 
function during embryogenesis [3, 24]. For angiogenesis to occur, endothelial cells (EC) 
must initiate a multi-stage program of basement membrane degradation, polarity 
switching, proliferation, and migration into the surrounding matrix [4] [5]. Perturbations 
of angiogenic pathways during development often lead to early embryonic lethality.  
Proper angiogenesis requires that EC establish and modify cell-cell interactions 
with neighboring EC. Several types of EC junctions are involved in blood vessel 
expansion, including tight and adherens junctions, and modulation of adherens 
junctions is a critical first step in new blood vessel formation [93] [94]. VE-cadherin is a 
key component of EC adherens junctions, and homotypic binding between VE-cadherin 
molecules on adjacent EC sets up cell-cell interactions [66]. Adherens junctions are 
involved in junction remodeling in sprouting vessels and aid in junction stabilization of 
large vessels, such as the developing aorta [75]. Endothelial cell-cell interactions also 
regulate vascular permeability and barrier function, and disruption of adherens junctions 
results in increased EC permeability, leading to hemorrhage and edema  [93] [95, 96] 
[91].  
Bone Morphogenetic Protein (BMP) signaling regulates angiogenesis, with 
certain pathway components either promoting or inhibiting angiogenesis [46] [97]. In 
canonical signaling, BMP ligands bind cell-surface Type II and Type I receptors that 
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form heterotetrameric complexes. Phosphorylation of Type I receptors by Type II 
receptors triggers phosphorylation of receptor associated SMADs (R-SMADs), which in 
BMP signaling are SMADs 1, 5, and 8 [98]. R-SMADs then bind to a common SMAD, 
SMAD4, and translocate into the nucleus to regulate the expression of target genes [34] 
[99].  
  BMP-induced sprouting via Bmp2b in zebrafish is exclusive to the caudal vein 
plexus and absent in the dorsal aorta (DA) during development [23]. BMP signaling also 
promotes angiogenesis in Human Umbilical Vein Endothelial Cells (HUVEC), as BMP2 
and BMP6 ligands increase lateral vessel branching [15]. In contrast, BMP9 functions 
as an anti-angiogenic signal, inducing quiescent EC and mature networks lacking 
growth features [42] [43] [44]. Both pro- and anti-angiogenic BMP signaling are 
important in sprouting angiogenesis in the early postnatal retina. Vascular deletion of 
either the Type II receptor BMPR2 or the Type I receptors ALK2/ACVR1 or 
ALK3/BMPR1A leads to reduced sprouting and/or branching, while vascular deletion of 
Alk1 leads to excess sprouting [41]. Although BMP signaling in the vasculature is 
considered to be “context-dependent”, it is not clear at the molecular level why some 
vessels respond to BMP signals with sprouting angiogenesis, while others do not.   
Numerous cell extrinsic negative regulators of BMP influence signaling, but there 
are few identified cell-intrinsic negative regulators of BMP signaling [100] [53]. SMAD6 
is one such cell-intrinsic negative regulator of BMP signaling expressed in EC [56] [101]. 
We recently showed that SMAD6 is anti-angiogenic in an in vitro 3D angiogenesis 
assay and in vivo in zebrafish [15]. Mice globally lacking Smad6 primarily die 
embryonically and perinatally, and surviving mice exhibit cardiovascular defects and 
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hypertension [58]. However, it is unclear how loss of Smad6 affects murine embryonic 
vascular development and angiogenesis. 
Here we investigated the role of SMAD6 in developing murine blood vessels and 
identify a novel role for SMAD6 in vessel stability associated with changes in adherens 
junctions in vivo and in vitro. We found that mouse embryos lacking Smad6 function 
displayed hemorrhage, suggesting increased vessel permeability. SMAD6 expression 
was localized to a subset of vessels developmentally, with limited non-vascular 
expression, and SMAD6 loss resulted in increased sprouting and branching in the early 
postnatal retina, accompanied by mis-localized VE-cadherin. These results point to a 
previously unappreciated role for SMAD6 in developmental angiogenesis, with effects 
on both sprouting and vessel stability that likely account for some of the context-
dependent outputs of BMP signaling in the vasculature. 
 
2.3 Materials & Methods 
Mouse and embryo handling 
All experiments involving animals were performed with approval of the UNC-CH 
IACUC Committee. Generation of Smad6-/- mice was previously described [58]. 
Smad6+/- embryos were thawed and injected into pseudo-pregnant females by the 
Mutant Mouse Resource and Research Center at University of North Carolina. All mice 
and embryos were on a CD1 background. Embryos of indicated stages were dissected 
and fixed in 4% paraformaldehyde (PFA) overnight, then stored in phosphate-buffered 
saline (PBS) at 4°C. Embryos were embedded in paraffin and sectioned at 10µm. 
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Embryo staining 
For whole mount LacZ staining, embryos were fixed with glutaraldehyde fix 
solution (5mM EGTA, 2mM MgCl2, 0.2% glutaraldehyde in PBS) for 20 min, washed in 
X-gal wash buffer (2mM MgCl2, 0.02% Nonidet P40, in 0.1M sodium phosphate) and 
stained for b-galactosidase with X-gal staining solution (5mM potassium ferrocyanide, 
5mM postassium ferricyanide, 1mg/mL X-gal in X-gal wash buffer) overnight at 37°C. 
Hemotoxylin & Eosin staining was performed on sections according to standard 
protocols [102].  
 
iDISCO and light-sheet imaging 
Staged embryos were stained for light-sheet imaging using the iDISCO protocol 
(including all solutions in protocol) to label large tissues [103]. Briefly, embryos were 
fixed overnight in 4% PFA at 4°C, then washed with PBS and subjected to the non-
methanol pretreatment. Embryos were permeabilized for 1 day in permeabilization 
solution at 37°C, then blocked in blocking solution for 1 day at 37°C prior to incubation 
with PECAM primary antibody (1:20, BD Pharmingen- 550274) in PTwH solution (0.2% 
Tween-20, 10 µg/µL Heparin in PBS) with 5% DMSO + 3% donkey serum for 2 days at 
37°C. Embryos were washed, incubated in Alexa-fluor-conjugated anti-rat secondary 
antibody (1:200) in PTwH solution with 3% donkey serum for 2 days at 37°C, then 
washed, dehydrated in methanol and cleared by incubating and storing in DiBenzyl 
Ether at RT. Embryos were imaged on a light-sheet microscope (Ultramicroscope II, 
LaVision Biotec). Images were processed using Imaris (Bitplane) software. 
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Retina acquisition and staining 
Mouse eyeballs were collected, fixed in 4% PFA for 1 hr, dissected and stored in 
PBS at 4 °C [104]. For immunofluorescent staining, retinas were permeabilized with 
0.2% Triton X-100 for 1 hr at RT, then blocked with CAS-block (Life Technologies- 00-
8120), for 1 hr at RT, followed by overnight incubation with VE-cadherin primary 
antibody (1:100, Santa Cruz- sc-28644) at 4°C. Retinas were washed with PBS, 
followed by incubation with Alexa fluor-conjugated secondary antibody (1:500) and 488-
conjugated Isolectin-IB4 (1:100, Life Technologies- I21411) for 4 hr at RT. Retinas were 
washed in PBS before mounting using Vectashield Hard Set (Vector laboratories). 
 
siRNA transfection  
HUVEC (Lonza) were transfected with non-targeting siRNA (Life Technologies- 
4390847) or SMAD6 siRNA (Life Technologies- 4392420, s8410, s8411) using the 
standard Lipofectamine 3000 (Invitrogen- L3000008) manufacturer’s protocol. Briefly, 
HUVEC were seeded to be ~70-90% confluent at the time of transfection in EBM-
2+EGM-2 BulletKit (Lonza- CC-3156 and CC-3162, respectively). siRNA was diluted in 
opti-MEM media at 10nM and incubated for 10 min at RT before adding in 
Lipofectamine reagent diluted in opti-MEM (1:1 ratio) and incubated for 20 min at RT. 
The DNA-lipid complex was then added to HUVEC in antibiotic-free media (EBM-2 
+EGM-2 BulletKit-gentamicin) and incubated overnight at 37°C.  Media was changed 
the following morning to allow HUVEC to recover and experiments were started 24 
hours after transfection. Cells were analyzed by western blotting to verify knockdown 
efficacy [15].  
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Micropattern plating 
H-pattern chips were purchased from CYTOO Inc. (CYTOO Chips, cytoo.com) 
and used according to the manufacturer’s recommendation. Chips were placed in a 6-
well plate and coated with 5µg/mL fibronectin in PBS for 30 min at 37°C, then 4mL of 
HUVEC resuspended at 15,000 cells/mL were added to each well. Cells were allowed 
to attach in the incubator for 20 min before rinsing and addition of new media. To 
observe 2 cells on a single H-pattern, cells were incubated overnight and serum-starved 
the following morning for 6 hr in 0.1% FBS in opti-MEM before treating with vehicle 
(4mM HCl, 0.5% BSA) or human BMP6 at 200ng/mL (R&D Systems- 507-BP-020) for 1 
hr at 37°C. The chips were then fixed and stained with VE-cadherin and DRAQ7 (to 




Internalization assays were performed essentially as described [105] [106], with 
slight modification. For VE-cadherin internalization, HUVEC plated on 0.1% gelatin-
coated coverslips and grown to confluency were washed quickly with chilled PBS+ (PBS 
supplemented with Ca+2 and Mg+2, ThermoFisher- 14040182) on ice at 4°C. Following 
washing, HUVEC were incubated with cold blocking/internalization solution (EBM-2 
supplemented with 0.5% w/v BSA) for 30 min on ice at 4°C to prevent internalization. 
HUVEC were incubated with VE-cadherin BV6 primary antibody (1:100, Enzo- ALX-
803-305-C100) in chilled blocking solution for 2 hr at 4°C to label the cell surface pool of 
VE-cadherin (BV6 binds extracellular domain of VE-cadherin), then washed quickly with 
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cold PBS+ before adding warmed (37°C) internalization medium (EBM-2 with vehicle or 
BMP6 treatment) and incubating at 37°C for 1 hr to activate endocytosis. Control cells 
were left at 4°C to show no VE-cadherin was internalized. HUVEC were then incubated 
in an acid wash (0.5 NaCl/0.2M acetic acid in water) for 4 minutes at 4°C. Control cells 
with no acid wash reveal VE-cadherin is labeled at the cell surface. Cells were then 




HUVEC in micropattern experiments were fixed for 10 min in 4% PFA, washed 
with PBS, then permeabilized for 20 min in 0.2% Triton X-100. Cells were blocked for 1 
hr at RT with CAS-block (Life Technologies- 00-8120), then incubated in VE-cadherin 
primary antibody (1:100, Cell Signaling- D87F2) overnight in CAS-block at 4°C. Cells 
were washed in PBS, then incubated with Alexa-fluor-conjugated anti-species 
secondary antibodies (1:500) and DRAQ7 (1:1,000, Abcam- ab109202) in CAS-block 
for 3 hr at RT. For internalization experiments, after VE-cadherin labeling, internalization 
and subsequent fixation, HUVEC were incubated with Alexa-fluor-conjugated phalloidin 
(1:250, Invitrogen- A12381) plus Alexa-fluor-conjugated anti-mouse secondary antibody 
(1:500) and DRAQ7 in CAS-block for 3 hr at RT. Coverslips were mounted onto slides 
using Fluoro-gel in Tris buffer (Electron Microscopy Sciences- 17985-10) and sealed 
with nail polish. 
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 Imaging  
All HUVEC fluorescent imaging was done using an Olympus FV1200 Laser 
Scanning Confocal Microscope and Flow View software. All embryo section images 
were acquired using a Zeiss Imager A2 AX10 microscope and Jenoptik camera. 
 
Statistical analysis 
Normalized datasets were graphed and analyzed using PRISM. Chi-square test 
was used to determine discrepancy between observed and expected numbers of a total 
of 133 Smad6+/+, Smad6+/-, and Smad6-/- mice at P0 from Smad6+/- intercrosses. For 
two-sample data sets with equal variances (control versus a single experimental 
condition) unpaired, two-tailed Student's t-test was used along with a Mann-Whitney 
post-hoc test. For data sets with greater than two conditions and equal variances, one-
way ANOVA with Tukey's post-hoc test was used. *P≤0.05, **P≤0.01, ***P≤0.001, 




Loss of Smad6 is Lethal with Moderate Penetrance and Vessel Hemorrhage  
Global loss of Smad6 results in embryonic and postnatal lethality with moderate 
penetrance [58] [59]. Surviving adult mice have hyperplastic thickening of the cardiac 
valves, defects in outflow tract septation, and hypertension [58]. To begin our studies of 
SMAD6 function in developing vessels, we analyzed the genotypes of progeny of a 
Smad6+/- intercross at P0 (Table 2.1) and found significantly fewer Smad6-/- mutant mice 
than expected, suggesting embryonic lethality with partial penetrance. Of the mutant 
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mice that survived to birth, most of these died within 2-7 days of birth (data not shown). 
We next examined embryos at embryonic day (E)15.5 for developmental defects. 
Because surviving adult Smad6-/- mutant mice were reported to have heart valve 
defects [58], we examined H&E stained sections through nascent heart valves and 
found no evidence of hyperplastic thickening or other defects (Figure 2.1A-B). We next 
broadly examined the embryonic vasculature via light-sheet microscopy, using a 
PECAM antibody to visualize all blood vessels. We saw no obvious gross vascular 
patterning changes in E15.5 Smad6-/- mutant embryos, suggesting that if sprouting 
angiogenesis is affected, remodeling subsequent to sprouting may rescue any initial 
defects (Figure 2.1C-F). Further examination of mutant embryos revealed areas of 
hemorrhage, which could be seen as early as E12.5 (data not shown) and were 
consistent by E15.5 (Figure 2.1G-H). Hemorrhage was noted at multiple locations in the 
mutant embryos, including in the skin (Figure 2.1I-J) and in brown fat pads (Figure 
2.1K-L). Collectively, these results indicate that Smad6 deletion leads to hemorrhage of 
embryonic vessels in the absence of obvious patterning defects. Since hemorrhage 
often results in lethality, we propose that the observed embryonic and early postnatal 
lethality is downstream of vascular hemorrhage.  
 
SMAD6 is Selectively Expressed in a Subset of Vessels Developmentally  
The embryonic vascular hemorrhage phenotype in the absence of obvious non-
vascular defects in Smad6-/- mutant mice suggested that SMAD6 expression may be 
primarily localized to developing blood vessels during mouse development. An earlier 
study showed SMAD6 expression in the cardiac outflow tract and atrioventricular 
cushion of embryos [58]. We examined expression using the LacZ knock-in reporter in 
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the locus as a surrogate for SMAD6 expression in the Smad6-/- background, since we 
did not see gross vessel patterning defects in the mutant embryos. LacZ expression 
was detected in the heart and cardiac outflow tract at E9.5 (Figure 2.2A). At E10.5, 
LacZ was expressed in the heart and dorsal aorta (Figure 2.2B-C), as the dorsal aorta 
begins to stabilize. At E13.5, 15.5 and 17.5, LacZ expression was seen in the 
descending aorta and in intercostal arteries emanating from the aorta in Smad6-/- 
embryos (Figure 2.2D, E, G), while LacZ expression was not detectable in these 
vessels in Smad6+/+ embryos (Figure 2.2F). At these times, reporter expression was 
also seen in the outflow tract and heart valve (data not shown). At E13.5-15.5, LacZ 
expression was detected in the branchial arch arteries, including the common carotid 
arteries and the left and right subclavian arteries (Figure 2.2D, H), and in vessels in the 
embryonic head (Figure 2.2I). Further analysis of the postnatal brain showed strong 
expression in conduit arteries such as the middle cerebral artery (Figure 2.2J-K) and 
basilar artery (Figure 2.2J). Sections of LacZ stained embryos revealed LacZ 
expression localized to EC of the aorta (Figure 2.2L), in smaller arteries throughout the 
embryo, including the vertebral arteries (Figure 2.2M), and in EC of postnatal brain 
vessels (Figure 2.2N-O). 
Taken together, these results indicate that SMAD6 is expressed in a subset of 
vessels during mouse development, and expression was not detectable in other tissues 
or cell types except for the heart, consistent with the vascular phenotype that was 
observed in Smad6-/- mutant embryos. Moreover, most of the vascular expression 
appears confined to developing arteries, and most veins and capillaries do not have 
detectable levels of reporter expression. Thus, the embryonic vascular hemorrhage 
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phenotype observed in the Smad6-/- mutant mice is likely due to primary defects in 
these vessels.  
 
SMAD6 Prevents Excessive Sprouting and Branching in Retinal Vessels  
To examine SMAD6 function during sprouting angiogenesis in developing 
vessels that are known to respond to manipulations of BMP signaling [41], we analyzed 
the postnatal retinal vasculature in pups that survived birth (Table 2.1). Retinal vessels 
develop by spreading radially from the optic nerve over the surface of the retina, starting 
at postnatal day 0 (P0). Vessels closer to the to the optic nerve undergo remodeling and 
become more stable and quiescent, whereas vessels at the vascular front are newly 
formed [107] [108] [109]. We hypothesized that in this area of robust sprouting 
angiogenesis loss of Smad6 would lead to increased vessel sprouting and branching. 
The retinal vasculature of P4 Smad6-/- mutant mice appeared denser compared to 
Smad6+/+ littermate controls, but radial expansion was not compromised (Figure 2.3A-
C), indicating no developmental delay. Closer examination of the vascular front showed 
that Smad6-/- mutant retinas had significantly more sprouts than littermate controls 
(Figure 2.3D-F). Behind the vascular front, Smad6-/- mutant mice also had significantly 
more branching in the plexus, which is typically a more stable vascular bed (Figure 
2.3G-I). In Smad6-/- mutant retinas, vessels were often found in several layers (note 
depth-encoded images Figure 2.3G-H), suggesting a lack of normal quiescence and 
remodeling. Thus, SMAD6 is anti-angiogenic in the developing mouse retina. 
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SMAD6 Promotes Linear VE-cadherin Localization and Blunts Internalization   
The increased branching of Smad6-/- mutant vessels behind the vascular front 
suggested that these vessels did not undergo flow-mediated remodeling but rather 
remained active in sprouting. A hallmark of activated blood vessels is destabilized 
adherens junctions [4] [5]. Thus, we hypothesized that SMAD6 stabilizes EC adherens 
junctions, and we examined the localization of VE-cadherin, a major EC adherens 
junction protein, in the mutant retinal vessels. VE-cadherin localization is indicative of 
active (dispersed or serrated) or stabilized (straight line) junctions [81] [80] (Figure 
2.3J-K). In Smad6+/+ littermate controls VE-cadherin localization was mainly linear at 
the cell membrane (Figure 2.3J, L); in contrast, Smad6-/- mutant retinas had a striking 
dispersed and punctate pattern of VE-cadherin (Figure 2.3K, M). These results show 
that SMAD6 affects endothelial adherens junctions in vivo and suggest that SMAD6 is 
upstream of stabilized adherens junctions as blood vessels remodel.  
To further examine and quantify the effects of SMAD6 manipulations on EC 
adherens junctions, we examined the effects of reduced SMAD6 levels on junctions 
formed in HUVEC in micropatterns designed to hold 2 cells side-by-side [110]. HUVEC 
transfected with a non-targeting siRNA control (NT siRNA) showed predominantly linear 
VE-cadherin staining (Figure 2.4A, C), indicating that the junctions are likely stabilized. 
In contrast, HUVEC with reduced SMAD6 levels had a more serrated and/or punctate 
VE-cadherin pattern (Figure 2.4B-C), suggesting more active junctions and consistent 
with our hypothesis.  
Increased active junctions are often associated with elevated VE-cadherin 
endocytosis, and signaling through BMP6 increases VE-cadherin internalization in EC 
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[84] [85]. To determine whether SMAD6 KD increases VE-cadherin internalization, we 
performed an internalization assay on HUVEC transfected with either NT or SMAD6 
siRNA. We labeled VE-cadherin with an antibody (BV6) to the extracellular domain at 
4°C and allowed internalization to occur at 37°C in the absence or presence of BMP6 
ligand and with or without reduced SMAD6 levels. To distinguish between cell surface 
and internalized pools of VE-cadherin, we removed BV6 bound to cell surface VE-
cadherin with an acid wash and then quantified the internalized VE-cadherin pool. Prior 
to acid wash, VE-cadherin was detected and localized at the cell surface, presumably in 
adherens junctions, as predicted (Figure 2.4D-D’, I-I’). Control HUVEC kept at 4°C to 
prevent internalization did not show detectable VE-cadherin staining after acid wash, 
suggesting that the antibody-labeled protein remained in the junctions and was 
susceptible to acid wash removal (Figure 2.4E-E’, F’F’, J-J’, K-K’). Control HUVEC 
incubated at 37°C showed increased non-junctional VE-cadherin staining that increased 
significantly with BMP6 ligand incubation, suggesting VE-cadherin internalization 
(Figure 2.4G-G’, H-H’, N). SMAD6 siRNA treated HUVEC at 37°C showed significant 
non-junctional VE-cadherin staining in both control conditions and with addition of BMP6 
(Figure 2.4L-L’, M-M’, N). These results suggest that SMAD6 stabilizes endothelial cell-
cell junctions and prevents VE-cadherin endocytosis. 
 
2.5 Discussion 
This work reveals a required role for the negative BMP regulator, SMAD6, during 
mouse vascular development. The phenotype of embryonic vessel hemorrhage and the 
restriction of SMAD6 expression to specific vessels in the embryo indicate that SMAD6 
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normally functions to stabilize vessels and prevent leak and hemorrhage. This likely 
occurs via effects on endothelial cell-cell junctions, as adherens junctions are perturbed 
in Smad6 mutant mouse retinal vessels and EC with reduced SMAD6 levels. Ultimately, 
disruption of adherens junctions results in leakiness of EC monolayers [74] [111, 112]. 
Our data is consistent with a model whereby SMAD6 regulates a required switch from a 
pro-angiogenic phenotype to a quiescent phenotype in arteries during embryogenesis.  
BMP signaling is context dependent with diverse responses in EC [40]. We 
showed that BMP signaling is repressed in intersegmental vessels that sprout from 
arteries of zebrafish and active in the caudal vein plexus that sprouts from the axial vein 
[23]. Repressed BMP signaling correlates with Smad6 expression and Smad6 function 
in zebrafish arteries [15]. Although SMAD6 is also expressed in nascent heart valves in 
the mouse (Galvin et al., 2000 and this study), there is no apparent embryonic 
phenotype or obvious heart defect during embryogenesis in mice lacking Smad6 
function. Instead, mutant embryos have vascular hemorrhage, suggesting that blood 
vessel stability is compromised. SMAD6 expression during mouse embryogenesis 
appears restricted to a subset of vessels that are primarily arterial, indicating that 
SMAD6 normally functions to stabilize embryonic arteries. Thus, it is likely that some 
arteries require SMAD6 to stabilize as they transition from a pro-angiogenic to a 
quiescent phenotype.  
It is notable that amongst the many identified negative regulators of BMP 
signaling, such as Chordin, Noggin, and Gremlin, most act extracellularly to bind BMP 
ligand to prevent their interaction with BMP receptors [113] [51] [114]. SMAD6 and 
SMAD7 are among a minority of TGF-b family regulators that act intracellularly to 
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modify signaling responses. SMAD7 inhibits both TGF-b and BMP-induced SMAD 
signaling, however, SMAD6 preferentially inhibits BMP signaling [53]. Interestingly, a 
BMP intercellular regulator, BMPER, is also expressed in the vasculature during 
development and regulates endothelial barrier function in adult mice [115] [116]. These 
findings suggest that it is important to regulate the response of endothelial cells and 
vessels to incoming BMP ligand, and our findings show that Smad6 function is not 
redundant with either BMPER or SMAD7 in the developing vasculature.  
Our work also reveals a cellular mechanism for the reduced stability of 
developing vessels in vivo. Examination of postnatal retinal angiogenesis revealed 
increased vascular sprouting and branching in surviving pups lacking Smad6 function 
compared to littermate controls, consistent with our previous work showing that SMAD6 
is anti-angiogenic in a 3D sprouting model [15]. This exuberant angiogenesis in Smad6-
/- mutant pups was accompanied by reduced levels of VE-cadherin localized to cell-cell 
junctions. This suggests that junctions are less stable absent Smad6 function in vivo, 
and EC with reduced SMAD6 levels revealed increased VE-cadherin internalization in 
vitro, supporting this idea. We showed that SMAD6 negatively regulates BMP signaling 
in EC, and a recent report showed that BMP signaling decreased EC stability by 
inducing Src-dependent phosphorylation and internalization of VE-cadherin [15] [85]. 
Thus, it is likely that in endothelial cells SMAD6 normally modulates the extent to which 
VE-cadherin turnover is promoted by BMP signaling. This negative modulation appears 
to be functionally critical in developing vessels that express SMAD6 to prevent vessel 
destabilization and hemorrhage.    
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Our work provides compelling evidence that SMAD6 functions to stabilize blood 
vessels during development, as they transition from an active or pro-angiogenic 
phenotype to a more quiescent phenotype. Since most adult vessels are quiescent, this 
finding predicts that SMAD6 mutations in humans may affect vessel integrity, and 
SMAD6 mutations were associated with congenital cardiovascular malformation in 
recent studies [63] [62] . Taken together, this further understanding of how a negative 
regulator of BMP signaling, SMAD6, affects angiogenesis and endothelial cell activation 
in mice reveals critical roles for SMAD6 in both vascular development and homeostasis. 
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Chi-square (c2) test was performed with GraphPad software and revealed a significant 
(P value=0.0011) loss of Smad6-/- mice by postnatal day (P)0. df= degrees of freedom. 
 
c2=13.71, df=2, **P=<0.0011 
  
 
P0 Mice (total=133 (100%)) 
Smad6+/+ Smad6+/- Smad6-/- 
Observed Expected Observed Expected Observed Expected 
46 (35%) 33 (25%) 76 (57%) 67 (50%) 11 (8%) 33 (25%) 
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Figure 2.1 Loss of SMAD6 results in embryonic vessel hemorrhage at E15.5 
A-B, 10µm paraffin cross-sections of E15.5 heart valve primordia of indicated 
genotypes stained with Hematoxylin and Eosin (H&E). Arrow, valve primordium; scale 
bar, 100µm. C-F, Whole mount E15.5 embryos stained with PECAM to visualize blood 
vessels and imaged using light-sheet microscopy. C-D, lateral view; E-F, ventral view. 
Higher magnification insets reveal no significant vessel patterning differences between 
Smad6+/+ (C, E) and Smad6-/- (D, F) embryos. Scale bar, C-D,1000µm, E-F, 500µm. G-
H, E15.5 whole mount embryos showing hemorrhage in Smad6-/- embryo (H, arrow, 
hemorrhage); scale bar, 1000 µm. I-L, Cross-sections through 2 different E15.5 
Smad6+/+ (I, K) and Smad6-/- (J, L) embryos showing hemorrhage (arrow in J, L), 
stained with H&E; scale bar, 200µm. h, heart; nt, neural tube.   
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Figure 2.2 SMAD6 is selectively expressed in a subset of vessels 
developmentally. 
A-I, Whole embryos stained with LacZ (blue). J-K, cross sections of lacZ stained 
embryos, counterstained with eosin (pink) A, E9.5 embryo with LacZ expression in the 
heart and outflow tract (arrow, heart). B-C, E10.5 embryo showing LacZ expression in 
heart and initiation of expression in the dorsal aorta (DA) (arrows, DA). C) Higher 
magnification of DA staining in (B). D-G, Body cavities of E13.5 Smad6-/- (D), E15.5 
Smad6-/- (E), and E17.5 Smad6+/+ (F) and Smad6-/- (G) embryos with all organs 
removed to show LacZ expression in aorta (black arrows in D, G) and intercostal 
arteries (IA) (arrow in E), compared to only background in Smad6+/+ embryo (F) 
(Arrowhead in D is branchial arch arteries). H, E15.5 Smad6-/- branchial arch arteries 
(BAA) positive for LacZ expression. CCA- common carotid arteries, LSA- left subclavian 
artery, RSA- right subclavian artery. I, Blood vessels expressing LacZ in E15.5 Smad6-/- 
embryo head (arrows, vessels). J-K, Whole postnatal brains showing arterial LacZ 
expression; middle cerebral arteries (MCA), basilar artery (BA); (arrows J-K, MCA; 
arrowhead J, BA).  L, Cross-section showing LacZ staining in aorta of E15.5 Smad6-/- 
embryo (arrow, aorta); inset, higher magnification of aorta. M, E15.5 Smad6-/- embryo 
cross-section with staining in smaller vertebral arteries (arrows, vertebral arteries); inset, 
higher magnification of left vertebral artery. N-O, Cross-sections of postnatal brains; 
insets, higher magnification of indicated vessel.  Scale bars: A-I, 500µm; J-K, 1,000µm; 
L-O, 100µm.  
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Figure 2.3: SMAD6 regulates postnatal retinal angiogenesis.  
 
A-B, P4 retinas stained with Isolectin-IB4 (white) to visualize vessels; (A) Smad6+/+and 
(B) Smad6-/- littermates; scale bar, 100µm. C, Quantification of radial expansion (% 
vessel length/retina leaf length). ns, not significant. D-E, Examples of retinal vascular 
front of (D) Smad+/+ and (E) Smad6-/- littermates (yellow arrows, sprout tips); scale bar, 
100µm. F, Quantification of sprouts (# sprouts/length of front). G-H, Examples of retinal 
vascular plexus region, stained for Isolectin, with Z-stacks depth-encoded for Smad6+/+ 
(G) comparison to Smad6-/- littermates (H); scale bar, 50µm. I, Quantification of 
branching. J-K, Retinal vessels stained for VE-cadherin (white); scale bar, 50µm. L-M, 
Merged images of J-K, VE-cadherin (green) and Isolectin (red); scale bar, 50µm. 
Smad6+/+ (J, L) and Smad6-/- (K, M). ****P≤0.0001, statistical significance was assessed 
using a Student's t-test, Mann-Whitney post-hoc test, 3 replicates.  
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Figure 2.4: Reduced SMAD6 levels promote changes in EC junction morphology 
and VE-cadherin internalization. 
A-B, H-micropatterns; scale bar, 10µm. HUVEC transfected with NT (A) or SMAD6 
siRNA (B) and stained with VE-cadherin (green) to visualize adherens junctions and 
DRAQ7 (blue) to visualize the nucleus. C, Quantification of VE-cadherin area in 
micropatterns with EC of indicated manipulations. D-M, HUVEC internalization assay 
with indicated treatments; immunofluorescent staining for VE-cadherin (green); scale 
bar, 10µm. D’-M’, Merged images from D-M to include phalloidin (red) and DRAQ7 
(blue); scale bar, 10µm. D-D’, Control with no acid wash - VE-cadherin staining at cell 
surface in junctions before internalization at 37°C. E-E’, F-F’, J-J’, K-K’, Controls kept 
at 4°C and acid washed, with or without ligand and with indicated siRNA, showing no 
VE-cadherin staining. G-G’, H-H’, L-L’, M-M’, HUVEC with or without ligand and 
indicated siRNA treatment, labeled at 4°C with VE-cadherin, then incubated at 37°C 
prior to acid wash. N, Quantification of VE-cadherin internalization (% VE-cadherin area 
normalized to cell area). Statistics, one-way ANOVA with Tukey's post-hoc test, 
***P≤0.001; 3 replicates.  
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CHAPTER III: General Discussion 
3.1 Global deletion of Smad6 results in lethality and embryonic blood vessel 
hemorrhage with moderate penetrance 
 
 We demonstrate a majority of Smad6-/- mice die by P0, with only a 8% survival 
rate. Previous reports of Smad6-/- survival ranges from 3-13% with mouse strains 
playing an important role in phenotypic penetrance. In our studies, we used an outbred 
mouse strain (CD1), which has greater genetic diversity than inbred strains and is 
expected to yield higher phenotypic variability. Galvin et al. demonstrated lower survival 
of Smad6-/- mice on a pure inbred strain (3%) and higher survival on two mixed inbred 
backgrounds (9 and 13%) [58]. Estrada et al. observed 5% survival of Smad6-/- mice 24 
hours past birth on a different mixed background than the original study [59]. 
Interestingly, lethality of Smad6 mutants on our outbred background was comparably 
penetrant to mixed inbred strains used previously. However, it is possible that 
differences between previous studies and ours in observed phenotypes and SMAD6 
expression could be due to different background strains of mice. This demonstrates the 
importance of considering genetic backgrounds when analyzing mouse models and 
when possible, validating phenotypic results on another background. My studies may be 
more reflective of the human population, since outbred strains represent more genetic 
diversity that is inherently present in humans. 
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Our studies reveal a novel phenotype upon developmental Smad6 loss, with 2/3 
of mutant embryos showing visible blood vessel hemorrhage. We observed hemorrhage 
in Smad6-/- embryos as early as E12.5 and more consistently by E15.5; however, the 
embryonic hemorrhage phenotype is not fully penetrant. Some embryos at E15.5 show 
no visible hemorrhage and a few mutant mice live to adulthood and are fertile with no 
apparent problems. Phenotypic penetrance is influenced by many factors such as 
environmental changes, type of mutation, and changes in gene expression. For 
example, loss of Smad6 could be compensated for by other BMP antagonists and 
inhibitors. SMAD7 inhibits BMP signaling in a similar way to SMAD6, and it is possible 
that SMAD7 levels are elevated in Smad6-/- mice that survive past birth [53]. Galvin et 
al. and Estrada et al. did not report embryonic hemorrhage in their analysis of Smad6 
mutant mice. However, we did not reproduce past findings of thickened cardiac valves 
in Smad6-/- pups, suggesting that differences in mouse strains result in variable 
phenotypes. Thus, it will be important to evaluate the hemorrhage phenotype in mice 
with different genetic backgrounds. Future studies aimed at studying Smad6 loss in an 
inbred strain, where mice are more genetically identical, and determining whether 
embryonic hemorrhage is more or less penetrant, could provide insight into the 
mechanism of blood vessel rupture. In addition, our lab will use an inducible, endothelial 
cell specific Smad6 knockout mouse in order to delete Smad6 at specific stages of 
development and in adulthood. These studies will increase our understanding of 
SMAD6 function, specifically in blood vessels, throughout development.  
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3.2 SMAD6 is expressed in a subset of blood vessels developmentally 
Upon examination of SMAD6 expression, we found SMAD6 is predominantly 
expressed in select arteries throughout development, and not found in veins. Here, we 
demonstrated high SMAD6 expression in arteries such as the aorta, vertebral arteries, 
branchial arch arteries, and also in major arteries of a few organs such as the brain and 
the lung. SMAD6 is present in arterial endothelial cells, but not in surrounding smooth 
muscle cells or pericytes (data not shown). This finding suggests that SMAD6 
localization in arterial endothelial cells is required to prevent hemorrhage, and loss of 
SMAD6 leads to defects in endothelial cells that weaken the vessel barrier.  
We also observed SMAD6 expression in the outflow tract and valves of the heart 
(data not shown) in agreement with a previous study [58]. However, opposing a 
previous study, we detected no SMAD6 expression in the anterior ribs, cervical 
vertebrae, or tibia cartilage of E15.5 mutant embryos via LacZ reporter expression. The 
genetic approach of inserting a reporter gene into a locus to determine expression 
patterns is powerful and commonly used; however, it is possible that insertion may 
generate some changes in regulatory sequences, and thus the reporter gene 
expression may not consistently reflect the endogenous gene expression. Our studies 
and Galvin et al. used LacZ reporter activity as a readout for SMAD6 expression, while 
Estrada et al. used a SMAD6 antibody to determine localization. Because of variations 
in sensitivity and stability of mRNA and protein, we anticipate some minor differences 
between genetic approaches and conventional staining methods. It is important to verify 
our findings via the LacZ reporter with conventional methods, such as 
immunofluorescent staining of embryo tissue with an antibody to SMAD6. Despite a few 
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differences in expression analysis, the hemorrhage phenotype observed in our studies 
likely stems from defects in vessels with high SMAD6 expression.  
Other BMP pathway members, including antagonists, are spatially and 
temporally regulated during embryogenesis to limit BMP signaling [23, 52], and thus 
SMAD6 localization to developing arteries suggests a low BMP signaling atmosphere is 
required. Other BMP antagonists show high expression in the vasculature, such as the 
intracellular BMP inhibitor, BMPER, which selectively expressed in endothelial cells 
[115]. Interestingly, SMAD7 is expressed similarly to SMAD6 and is strongly expressed 
in the endothelium of major arteries as well as in the heart, again suggesting that the 
incomplete penetrance of hemorrhage in Smad6 mutant embryos could be due to 
functional redundancy with SMAD7 [117]. However, Smad7-deficient mice have distinct 
cardiac phenotypes, including ventricular septal defects and ventricular non-
compaction, compared to Smad6 mutant mice, which have cardiac valve defects in 
some background strains [58, 118]. No hemorrhage phenotypes have been reported in 
Smad7 loss of function studies. This may signify a high degree of functional specificity 
amongst BMP inhibitors. Deregulation of BMP signaling can lead to vascular 
malformations, such as HHT and CCMs. Taken together, the necessity of 
understanding the unique function of each BMP inhibitor to identify therapeutic targets 
to vascular malformations is apparent. 
It will be important to discover why some arterial endothelial cells express 
SMAD6 and why others do not. We hypothesize that SMAD6 functions to stabilize 
larger, mature arteries to maintain vessel quiescence in the developing embryo. 
Vasculature quiescence requires a stable endothelial barrier, and we show loss of 
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Smad6 results in hemorrhaging blood vessels, supporting our hypothesis that SMAD6 
expression is required for vessel stability. SMAD6 is “turned on” in the aorta at E10.0; at 
this developmental stage, the aorta has formed and sprouting of intercostal arteries is 
complete, thus the aorta is more stable and quiescent [119]. Similarly, SMAD6 
expression in intercostal arteries is not observed until E12.5 (instead of upon formation). 
These results suggest that as arteries mature in the developing embryo, BMP signaling 
must be limited by upregulating SMAD6 to keep endothelial cells in a resting state. A 
recent study demonstrated SMAD6 upregulation upon acquisition of vascular 
quiescence in endothelial cells isolated from the lungs, brain, and heart [120]. HUVEC 
overexpressing SMAD6 displayed reduced angiogenic potential, as determined by 
decreased migration and proliferation, again advocating for SMAD6 function in 
establishing vascular quiescence [120]. SMAD6 is anti-angiogenic in many models but it 
remains unclear whether loss of Smad6 results in increased sprouting angiogenesis 
during murine embryogenesis in the subset of arteries where it is expressed 
(Mouillesseaux et al., 2016, and this study). Rigorous analysis of sprouting from vessels 
(such as the middle cerebral artery of the brain, which has high SMAD6 expression) in 
wildtype and mutant embryos, will aid understanding of whether SMAD6 is anti-
angiogenic in mouse development, as in other models. Analysis of SMAD6 expression 
in a wound healing model would provide greater insight to its function in vascular 
maintenance. For example, if SMAD6 is expressed in stable, mature arteries, we predict 
that SMAD6 levels will be reduced in arteries close to the wound to allow for sprouting, 
but then increase in arteries after the healing process is complete.  
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Many genes, including Notch ligands and receptors, are selectively expressed in 
arteries vs. veins [15, 121-123]. Our lab recently reported that Notch signaling regulates 
SMAD6 levels to control endothelial cell responsiveness to BMP signaling in HUVEC 
and zebrafish [15]. Notch is required for arteriovenous specification and this raises the 
question of whether SMAD6 upregulation in arteries is Notch-dependent [123, 124]. 
However, we observed SMAD6 expression in only a subset of arteries, whereas Notch 
is more widely present in arteries from early in development; thus, it is questionable that 
SMAD6 arterial specific expression depends solely on the Notch status of the 
endothelial cell. Nevertheless, it would be interesting to determine SMAD6 expression in 
arteries of Notch loss-of-function mouse models and examine whether select arteries 
have higher Notch expression than others in wildtype mouse embryos. High Notch 
levels in arteries where SMAD6 is expressed would support that a threshold of Notch 
signaling is a limiting factor for SMAD6 expression.  
It is also possible that SMAD6 is induced by blood flow (laminar shear stress) in 
the mouse, as blood flow contributes to vessel stabilization and quiescence. SMAD6 
expression correlates to vessels known to have high levels of shear stress, such as the 
aorta, and prior studies demonstrate that SMAD6 is induced with laminar shear stress in 
vitro [125]. Knockdown of SMAD6 in an in vitro 3D angiogenesis assay with no blood 
flow results in increased sprouting angiogenesis, suggesting that SMAD6 is required to 
maintain vessel quiescence and network expansion irrespective of blood flow [15]. 
However, vessel rupture was not observed in our in vitro 3D model (data not shown), 
and thus it is possible that SMAD6 is induced in larger arteries with high blood volume 
to further stabilize the endothelial barrier and prevent hemorrhage. In other words, 
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SMAD6 may be required in high shear stress arteries to protect endothelial integrity 
once blood flow is initiated. Junctional proteins, such as VE-cadherin and ZO-1, are also 
upregulated by physiologic shear stress levels to enhance junctional tightness and 
prevent barrier impairment. It is possible that SMAD6 localization in high shear stress 
arteries works in concert with junctional proteins to increase stability of those arteries. It 
will be critical to understand how SMAD6 contributes to endothelial cell permeability in 
presence and absence of blood flow. In conclusion, our studies reveal an intriguing 
expression pattern of SMAD6 during mouse development and it is important to 
understand how this is regulated and the downstream outcomes when this expression 
pattern is perturbed.  
 
3.3 SMAD6 is anti-angiogenic in the postnatal retina 
 Our studies reveal SMAD6 is required to limit sprouting angiogenesis in the 
postnatal mouse retina. This matches previous data showing reduced SMAD6 levels 
results in increased angiogenesis in a 3D angiogenesis assay and in zebrafish [15]. 
Decreasing BMP signaling by endothelial-specific deletion of the BMP receptors, 
Bmpr2, Alk2, and Alk3 results in reduced sprouting at the retina front and branching in 
the plexus [41]. In accordance, we show that Smad6 deletion, and thus increased BMP 
signaling, increases sprouting at the retinal front and branching in the plexus. As we 
sought to understand how SMAD6 functions to regulate sprouting, we examined 
adherens junctions, as junctional contacts must first be rearranged for sprouting to be 
initiated [4, 5]. Here, we reveal a novel function for SMAD6 in regulation of organization 
of the adherens junction protein, VE-cadherin. Increased sprouting and branching in the 
retina vasculature may result from aberrant VE-cadherin localization resulting in 
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activated endothelial cells that insistently initiate sprouting angiogenesis. Disruption of 
VE-cadherin localization increases permeability and reduced VE-cadherin levels lead to 
hemorrhage in zebrafish, suggesting that hemorrhage observed in Smad6 mutant 
embryos may result from disrupted endothelial adherens junctions [90]. However, no 
visible hemorrhage was observed in Smad6-/- retinas with disorganized VE-cadherin. 
This is possibly due to limited blood flow in P4 retinal vessels, and consequently a 
disruption in endothelial barrier integrity may not yield a phenotypic outcome. We 
propose that SMAD6 functions to stabilize junctions for proper formation of the blood 
vessel network during early retina vessel development, and functions later in the retina 
vasculature to maintain a quiescent network and a strong endothelial barrier. Inducible 
deletion of SMAD6 in the retina vasculature after remodeling occurs and shear stress 
levels are high will elucidate whether SMAD6 functions to prevent vessel rupture in the 
postnatal retina.  
 We observed Smad6 expression in the postnatal retina by qPCR and Western 
blot analysis of retina lysates (data not shown). However, the precise localization of 
SMAD6 in the retina is unknown and it is unclear whether SMAD6 expression remains 
arterial and endothelial in this vascular bed. BMP ligands are expressed in the retina 
and BMP receptors are enriched in all endothelial cells of retina vessels, regardless of 
an arterial or venous identity [41]. In addition, defects in sprouting were not specific to a 
certain vessel type in Bmpr2, Alk2 and Alk3 knockout mice, suggesting that BMP 
responsiveness in this particular vascular bed may be more complex than in other 
models where only venous endothelial cells respond to BMP ligand [15, 23, 41]. We 
predict that because arterial and venous endothelial cells respond to BMP signaling in 
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the retina, SMAD6 is required in all endothelial cells to limit BMP signaling levels for 
proper blood vessel network expansion. Our studies support this idea as defects in 
sprouting and branching in Smad6-deficient mice appear to affect the entire vascular 
plexus and front, instead of being limited to certain vessels. Future studies examining 
precise SMAD6, as well as other BMP inhibitors, localization will be needed to further 
our understanding of how BMP signaling is regulated in the postnatal retina to form a 
proper vessel network. 
   
3.4 SMAD6 is required for localization of VE-cadherin 
 Here, we demonstrate that loss or reduction of SMAD6 results in disorganized 
and aberrant VE-cadherin localization in vitro and in the postnatal mouse retina as well 
as increased VE-cadherin internalization in HUVEC. Changes in junctional tightness, 
specifically by reduction of tight junction proteins, increases endothelial permeability, 
leading to vascular leakage in capillaries and postcapillary venules [69]. In arteries, 
hemorrhage can result when the vessel barrier is compromised by alterations in 
junctional contacts. Therefore, hemorrhage in Smad6-/- embryos may result from a 
weakened endothelial cell barrier. My studies reveal an unknown function of SMAD6 in 
stabilization of blood vessels by promoting a strong endothelial cell-cell junction.  
 To further elucidate the regulation of VE-cadherin by SMAD6, future studies 
examining the precise mechanism are needed. BMP signaling through BMP6 ligand 
was recently reported to increase permeabilization of endothelial cells by inducing Src-
dependent phosphorylation and internalization of VE-cadherin, providing initial insights 
into the molecular mechanism of BMP-induced vascular permeability [85].  Our studies 
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demonstrate that SMAD6 knockdown induces VE-cadherin endocytosis in HUVEC, and 
knockdown of SMAD6 also results in increased SRC phosphorylation (data not shown). 
These results suggest that SMAD6 is a critical component in the mechanism of BMP 
regulation of barrier function.  
It is unclear whether SMAD6 influences VE-cadherin internalization by 
suppressing R-SMAD signaling or regulates VE-cadherin at level of the receptors, 
independent of R-SMAD outputs. SMAD6 inhibits BMP signaling in many ways, yet the 
mechanism of BMP inhibition in endothelial cells is unknown (See Figure 1.1 for 
possible mechanisms). It will be important to examine the critical ways SMAD6 acts in 
endothelial cells to inhibit BMP, as understanding these mechanisms will provide insight 
into junctional phenotypes observed with SMAD6 depletion. We propose a model 
whereby SMAD6 blocks phosphorylation of R-SMADs by binding to BMP Type I 
receptors in the absence of BMP ligand. Ligand binding results in release of SMAD6 
from the Type I receptor and subsequent binding to BMPRII [57]. This mechanism of 
BMP inhibition puts SMAD6 at the level of the receptors, which have been shown to 
associate with VE-cadherin, and perhaps begins to explain SMAD6 effect on VE-
cadherin localization [85]. SRC is known to bind BMPRII, and we speculate that ligand-
induced SMAD6 binding to BMPRII causes the release of and subsequent activation of 
SRC (by revealing its active kinase), leading to phosphorylation of VE-cadherin to 
weaken the cell-cell junction (See model in Figure 1.2). Disruption of the endothelial 
junction thus results in sprouting angiogenesis and increased vessel permeability. As 
this model is untested, relationships between SMAD6 and the receptors, R-SMADs, and 
VE-cadherin could be examined by biochemical and functional assays. Additionally, 
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SRC knockdown or VE-cadherin overexpression combined with SMAD6 knockdown 
would help determine if adherens junction organization and endothelial cell permeability 
can be rescued.  
In vivo examination of the postnatal retina vasculature revealed similar defects in 
VE-cadherin localization with Smad6 loss as well as vessel remodeling defects. 
However, it remains unknown whether VE-cadherin localization is disrupted in Smad6 
mutant embryos in arteries that express SMAD6. SRC is activated by venous (lower) 
shear stress to promote VE-cadherin internalization and regulate permeability [74].  
Because our studies show embryonic SMAD6 expression particularly in arterial 
endothelial cells undergoing higher shear stress levels, we propose that SMAD6 inhibits 
SRC activation in quiescent arteries. Smad6 loss potentially leads to an increase in 
phosphorylation of VE-cadherin in arteries, similar to that seen in veins. These studies 
would provide insight into the mechanism of hemorrhage seen in most Smad6-/- mice. 
 
3.5 Summary  
 
 In conclusion, I have found that SMAD6 acts to prevent hemorrhage during 
embryonic development, and in regulating angiogenesis and remodeling in the postnatal 
retina vasculature. I have also shown that loss of SMAD6 leads to disorganized 
adherens junctions both in vitro and in vivo. My studies reveal novel functions of 
SMAD6 as a stability factor, maintaining vessel quiescence to prevent aberrant 
angiogenesis and vessel rupture. This information aids understanding of BMP signaling 
in angiogenesis and barrier function and informs SMAD6 disease states.   
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